Interleukin 17 as a central component of the pathogenesis of pain associated with immunoinflammatory process: A new “target” of pharmacotherapy

Modern pathogenetic therapy of inflammatory rheumatic diseases (IRD) is aimed not only at reducing disease activity (although achieving remission and low disease activity remains the main goal of treatment), but also at eliminating as quickly and completely as possible the main symptoms that cause a decrease in the quality of life of patients. Particular importance is attached to effective control of chronic pain – the main and most distressing manifestation of IRD. To solve this problem, the pathogenesis of chronic pain in IRD continues to be actively studied, aimed at finding new ”targets” of pharmacotherapy. Thus, the role of central sensitization (CS) and comorbid fibromyalgia in the formation of clinical manifestations of IRD is now clearly proven. Signs of CS, depending on the instrument of its detection, are determined in 20–40% of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).

Interleukin (IL) 17 plays a fundamental role in the development of chronic pain in IIRD. This cytokine takes a leading position in the development of the ”cytokine cascade”, inducing the synthesis of various cytokines and chemokines, as well as chemotaxis and activation of neutrophils and T cells. Induction of synthesis of inflammatory mediators (including prostaglandin E2) determines the role of IL-17 in activation of nociceptors and their sensitization. IL-17 also takes an active part in neuroimmune interactions by activating glia cells and affecting receptors present on the membrane of neurons of the posterior horns of the spinal cord. This defines the role of IL-17 as one of the inductors of CS development. Pharmacologic blockade of IL-17 is a known pathway to suppress the activity of IIRPs such as PsA and AxSpA. However, this mechanism also allows for significant effects on chronic pain. In particular, the IL-17 inhibitor ixekizumab has shown high analgesic potential in a series of studies in PsA and AxSpA (SPIRIT-P1 and SPIRIT-P2, COAST V and COAST W). It is important to note that this drug demonstrated a very rapid analgesic effect: pain intensity was significantly reduced already 7 days after the first injection. These data suggest a specific effect of ixekizumab on the nociceptive system, independent of the anti-inflammatory effect. This fact allows us to consider ixekizumab as a drug of choice for the treatment of patients with PsA and AxSpA who experience severe pain and have signs of CS and fibromyalgia.

1. Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):5-20 (In Russ.)

2. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. doi: 10.1038/s41584-022-00827-y

3. Hackett S, Coates LC. Outcome measures in psoriatic arthritis: Where next? Musculoskeletal Care. 2022;20(Suppl 1):22-31. doi: 10.1002/msc.169

4. Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken). 2013;65(8):1299-1306. doi: 10.1002/acr.2199

5. Karateev AE. Patient’s reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases. Modern Rheumatology Journal. 2021;15(5):121-127 (In Russ.)

6. Yang Z, Li S, Wang X, Chen G. Health state utility values derived from EQ-5D in psoriatic patients: A systematic review and metaanalysis. J Dermatolog Treat. 2022;33(2):1029-1036. doi: 10.1080/09546634.2020.1800571

7. Kedra J, Claudepierre P, Flipo RM, Garrido-Cumbrera M, AlliotLaunois F, Desfleurs E, et al. Impact of axial spondyloarthritis on quality of life: Results from the European Map of Axial Spondyloarthritis (EMAS) study in France. J Rheumatol. 2022;49(10):1176-1178. doi: 10.3899/jrheum.210864

8. Haridoss M, Bagepally BS, Natarajan M. Health-related quality of life in rheumatoid arthritis: Systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia. Int J Rheum Dis. 2021;24(3):314-326. doi: 10.1111/1756-185X.14066

9. McWilliams DF, Dawson O, Young A, Kiely PDW, Ferguson E, Walsh DA. Discrete trajectories of resolving and persistent pain in people with rheumatoid arthritis despite undergoing treatment for inflammation: Results from three UK cohorts. J Pain. 2019;20(6):716-727. doi: 10.1016/j.jpain.2019.01.001

10. Kodumudi V, Rajput K. Pain management in painful psoriasis and psoriatic arthropathy: challenging and intricately intertwined issues involving several systems. Curr Pain Headache Rep. 2021;25(6):36. doi: 10.1007/s11916-021-00952-5

11. Pathan EMI, Inman RD. Pain in axial spondyloarthritis: Insights from immunology and brain imaging. Rheum Dis Clin North Am. 2021;47(2):197-213. doi: 10.1016/j.rdc.2020.12.007

12. Schwartzman S, Ruderman EM. A road map of the axial spondyloarthritis continuum. Mayo Clin Proc. 2022;97(1):134-145. doi: 10.1016/j.mayocp.2021.08.007

13. Kiltz U, Baraliakos X, Regel A, Bühring B, Braun J. Causes of pain in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2017;35(Suppl 107):102-107.

14. Aouad K, Moysidou G, Rakotozafiarison A, Fautrel B, Gossec L. Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients. Semin Arthritis Rheum. 2021;51(4):888-894. doi: 10.1016/j.semarthrit.2021.06.008

15. Beckers E, Hermans K, Van Tubergen A, Boonen A. Fatigue in patients with rheumatic and musculoskeletal diseases: A scoping review on definitions, measurement instruments, determinants, consequences and interventions. RMD Open. 2023;9(3):003056. doi: 10.1136/rmdopen-2023-003056

16. Chmielewski G, Majewski MS, Kuna J, Mikiewicz M, KrajewskaWłodarczyk M. Fatigue in inflammatory joint diseases. Int J Mol Sci. 2023;24(15):12040. doi: 10.3390/ijms241512040

17. Hill J, Harrison J, Christian D, Reed J, Clegg A, Duffield SJ, et al. The prevalence of comorbidity in rheumatoid arthritis: A systematic review and meta-analysis. Br J Community Nurs. 2022;27(5):232- 241. doi: 10.12968/bjcn.2022.27.5.232

18. Machin AR, Babatunde O, Haththotuwa R, Scott I, BlagojevicBucknall M, Corp N, et al. The association between anxiety and disease activity and quality of life in rheumatoid arthritis: A systematic review and meta-analysis. Clin Rheumatol. 2020;39(5):1471-1482. doi: 10.1007/s10067-019-04900-y

19. Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1481-1488. doi: 10.1016/j.semarthrit.2020.02.001

20. Zhao S, Thong D, Miller N, Duffield SJ, Hughes DM, Chadwick L, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: A systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):140. doi: 10.1186/s13075-018-1644-6

21. Mease PJ, Liu M, Rebello S, Kang H, Yi E, Park Y, et al. Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: Data from two Corrona registries. Rheumatol Ther. 2019;6(4):529-542. doi: 10.1007/s40744-019-00172-9

22. Sunzini F, Schrepf A, Clauw DJ, Basu N. The biology of pain: Through the rheumatology lens. Arthritis Rheumatol. 2023;75(5):650-660. doi: 10.1002/art.42429

23. Sebba A. Pain: A review of interleukin-6 and its roles in the pain of rheumatoid arthritis. Open Access Rheumatol. 2021;13:31-43. doi: 10.2147/OARRR.S291388

24. Cao Y, Fan D, Yin Y. Pain mechanism in rheumatoid arthritis: From cytokines to central sensitization. Mediators Inflamm. 2020;2020:2076328. doi: 10.1155/2020/2076328

25. Das D, Choy E. Non-inflammatory pain in inflammatory arthritis. Rheumatology (Oxford). 2023;62(7):2360-2365. doi: 10.1093/rheumatology/keac671

26. Minhas D, Murphy A, Clauw DJ. Fibromyalgia and centralized pain in the rheumatoid arthritis patient. Curr Opin Rheumatol. 2023;35(3):170-174. doi: 10.1097/BOR.0000000000000929

27. Rutter-Locher Z, Arumalla N, Norton S, Taams LS, Kirkham BW, Bannister K. A systematic review and meta-analysis of questionnaires to screen for pain sensitisation and neuropathic like pain in inflammatory arthritis. Semin Arthritis Rheum. 2023;61:152207. doi: 10.1016/j.semarthrit.2023.152207

28. Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: A systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453-1460. doi: 10.1093/rheumatology/key112

29. Sarzi-Puttini P, Zen M, Arru F, Giorgi V, Choy EA. Residual pain in rheumatoid arthritis: Is it a real problem? Autoimmun Rev. 2023;22(11):103423. doi: 10.1016/j.autrev.2023.103423

30. Michaud K, Pope J, van de Laar M, Curtis JR, Kannowski C, Mitchell S, et al. Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(11):1606-1616. doi: 10.1002/acr.24369

31. Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: A systematic review of real-world evidence. Rheumatol Ther. 2022;9(3):803-821. doi: 10.1007/s40744-022-00443-y

32. Webers C, Boonen A, Vonkeman HE, van Tubergen A. Factors associated with residual disease in axial spondyloarthritis: Results from a clinical practice registry. J Rheumatol. 2023;50(11):1430- 1438. doi: 10.3899/jrheum.2023-0194

33. Nasonov EL, Korotaeva TV, Dubinina TV, Lila AM. IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: New horizons. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):400-406 (In Russ.)

34. Brembilla NC, Boehncke WH. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023;14:1186455. doi: 10.3389/fimmu.2023.1186455

35. Sánchez-Rodríguez G, Puig L. Pathogenic role of IL-17 and therapeutic targeting of Il-17F in psoriatic arthritis and spondyloarthropathies. Int J Mol Sci. 2023;24(12):10305. doi: 10.3390/ijms241210305

36. Gao SJ, Liu L, Li DY, Liu DQ, Zhang LQ, Wu JY, et al. Interleukin-17: A putative novel pharmacological target for pathological pain. Curr Neuropharmacol. 2024;22(2):204-216. doi: 10.2174/1570159X21666230811142713

37. Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022;13:999407. doi: 10.3389/fimmu.2022.999407

38. Sun JL, Dai WJ, Shen XY, Lü N, Zhang YQ. Interleukin-17 is involved in neuropathic pain and spinal synapse plasticity on mice. J Neuroimmunol. 2023;377:578068. doi: 10.1016/j.jneuroim.2023.578068

39. Lee KM, Sherlock JP, Hamilton JA. The role of interleukin (IL)- 23 in regulating pain in arthritis. Arthritis Res Ther. 2022; 24(1):89. doi: 10.1186/s13075-022-02777-y.

40. Luo X, Chen O, Wang Z, Bang S, Ji J, Lee SH, Huh Y, Furutani K, He Q, Tao X, Ko MC, Bortsov A, Donnelly CR, Chen Y, Nackley A, Berta T, Ji RR. IL-23/IL-17A/TRPV1 axis produces mechanical pain via macrophage-sensory neuron crosstalk in female mice. Neuron. 2021; 109(17):2691-2706.e5. doi: 10.1016/j.neuron.2021.06.015.

41. Tabra SA, Abd Elghany SE, Amer RA, Fouda MH, Abu-Zaid MH. Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022; 41(11):3391-3399. doi: 10.1007/s10067-022-06300-1

42. Korotaeva TV. Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: What’s new? Modern Rheumatology Journal. 2021;15(2):106-111 (In Russ)

43. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al.; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709

44. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al.; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 201;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0

45. Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al.; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386

46. Coates LC, Mease P, Kronbergs A, Helt C, Sandoval D, Park SY, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional diseasemodifying antirheumatic drugs: SPIRIT-P1 and SPIRITP2 3-year results. Clin Rheumatol. 2022;41(10):3035-3047. doi: 10.1007/s10067-022-06218-8

47. Orbai AM, Gladman DD, Goto H, Birt JA, Gellett AM, Lin CY, et al. Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis. Clin Exp Rheumatol. 2021;39(2):329-336. doi: 10.55563/clinexprheumatol/c2lbri

48. Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al.; COAST-V and COAST-W Study Groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118

49. Deodhar AA, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Hunter T, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021;5(1):35. doi: 10.1186/s41927-021-00205-3

50. Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from 21 clinical trials. Rheumatology (Oxford). 2020;59(12): 3834-3844. doi: 10.1093/rheumatology/keaa189